Literature DB >> 34981233

Efficacy and safety of the "watch-and-wait" approach for rectal cancer with clinical complete response after neoadjuvant chemoradiotherapy: a meta-analysis.

Xuan Zhang1, Rong Ding2, JinSha Li1, Tao Wu1, ZhengHai Shen3, ShanShan Li4, Ya Zhang5, Chao Dong6, ZhongJun Shang7, Hai Zhou3, Ting Li1, GuoYu Li1, YunFeng Li8.   

Abstract

BACKGROUND: Watch-and-Wait (WW) approach is positioned at the cutting edge of non-invasive approach for rectal cancer patients who achieve clinical complete response (cCR) after neoadjuvant chemoradiotherapy (nCRT). This meta-analysis aimed to compare the clinical, oncologic, and survival outcomes of WW versus radical surgery (RS) and to evaluate the efficacy, safety, and possible superiority of WW.
METHODS: A systematic search for studies comparing WW with RS was conducted on MEDLINE, Ovid, Embase, Cochrane Library, and Web of Science databases. After screening for inclusion, data extraction, and quality assessment, statistical analysis was performed using Stata/SE14.0 software. Permanent colostomy (PC), local recurrence (LR), distant metastasis (DM), cancer-related death (CRD), 2-, 3-, and 5-year disease-free survival (DFS), and overall survival (OS) were analyzed using fixed effects or random-effects models depending on the heterogeneity.
RESULTS: Fourteen studies with moderate-high quality involving 1254 patients were included. Of these, 513 patients were managed with WW and 741 patients were subjected to RS. Compared to RS group, WW group had higher rate of LR (odds ratio OR = 11.09, 95% confidence interval CI = 5.30-23.20, P = 0.000), 2-year OS, and 3-year OS and had lower rate of PC (OR = 0.12, 95% CI = 0.05-0.29, P = 0.000). There were no significant between-group differences with respect to DM, CRD, 2-, 3-, and 5-year DFS (OR = 0.92, 95% CI = 0.81-1.03, P = 0.153), or 5-year OS (OR = 1.01, 95% CI = 0.28-3.63, P = 0.988).
CONCLUSION: The WW is a promising treatment approach and is a relatively safe alternative to RS for managing patients with rectal cancer who achieve cCR after nCRT. However, this modality requires rigorous screening criteria and standardized follow-up. Large-scale, multicenter prospective randomized controlled trials are warranted to further verify the outcomes of WW approach.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Complete response; Meta-analysis; Neoadjuvant chemoradiotherapy; Rectal cancer; Watch-and-wait approach

Mesh:

Year:  2022        PMID: 34981233     DOI: 10.1007/s00464-021-08932-x

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  37 in total

1.  Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.

Authors:  Shin Fujita; Takayuki Akasu; Junki Mizusawa; Norio Saito; Yusuke Kinugasa; Yukihide Kanemitsu; Masayuki Ohue; Shoichi Fujii; Manabu Shiozawa; Takashi Yamaguchi; Yoshihiro Moriya
Journal:  Lancet Oncol       Date:  2012-05-15       Impact factor: 41.316

2.  Colorectal cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ann Goding Sauer; Stacey A Fedewa; Lynn F Butterly; Joseph C Anderson; Andrea Cercek; Robert A Smith; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-03-05       Impact factor: 508.702

3.  Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.

Authors:  Claus Rödel; Torsten Liersch; Heinz Becker; Rainer Fietkau; Werner Hohenberger; Torsten Hothorn; Ullrich Graeven; Dirk Arnold; Marga Lang-Welzenbach; Hans-Rudolf Raab; Heiko Sülberg; Christian Wittekind; Sergej Potapov; Ludger Staib; Clemens Hess; Karin Weigang-Köhler; Gerhard G Grabenbauer; Hans Hoffmanns; Fritz Lindemann; Anke Schlenska-Lange; Gunnar Folprecht; Rolf Sauer
Journal:  Lancet Oncol       Date:  2012-05-23       Impact factor: 41.316

4.  Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer.

Authors:  Samantha K Hendren; Brenda I O'Connor; Maria Liu; Tracey Asano; Zane Cohen; Carol J Swallow; Helen M Macrae; Robert Gryfe; Robin S McLeod
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

Review 5.  Postoperative complications following surgery for rectal cancer.

Authors:  Bogdan C Paun; Scott Cassie; Anthony R MacLean; Elijah Dixon; W Donald Buie
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

6.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

7.  Low anterior resection syndrome and quality of life: an international multicenter study.

Authors:  Therese Juul; Madelene Ahlberg; Sebastiano Biondo; Eloy Espin; Luis Miguel Jimenez; Klaus E Matzel; Gabriella Jansson Palmer; Anna Sauermann; Loris Trenti; Wei Zhang; Søren Laurberg; Peter Christensen
Journal:  Dis Colon Rectum       Date:  2014-05       Impact factor: 4.585

8.  Urinary dysfunction after rectal cancer treatment is mainly caused by surgery.

Authors:  M M Lange; C P Maas; C A M Marijnen; T Wiggers; H J Rutten; E Klein Kranenbarg; C J H van de Velde
Journal:  Br J Surg       Date:  2008-08       Impact factor: 6.939

9.  Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer.

Authors:  James D Harrison; Michael J Solomon; Jane M Young; Alan Meagher; Phyllis Butow; Glenn Salkeld; George Hruby; Stephen Clarke
Journal:  Arch Surg       Date:  2008-04

10.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.